iodixanol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 3302 92339-11-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iodixanol
  • visipaque
dimeric contrast media; structure given in first source
  • Molecular weight: 1550.19
  • Formula: C35H44I6N6O15
  • CLOGP: -4.28
  • LIPINSKI: 3
  • HAC: 21
  • HDO: 13
  • TPSA: 339.09
  • ALOGS: -3.92
  • ROTB: 22

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.44 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 22, 1996 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 171.54 40.27 119 1969 283449 50319587
Urticaria 137.70 40.27 78 2010 129483 50473553
Acute generalised exanthematous pustulosis 98.15 40.27 29 2059 8909 50594127
Erythema 93.91 40.27 64 2024 146350 50456686
Contrast encephalopathy 88.37 40.27 12 2076 56 50602980
Rash maculo-papular 60.69 40.27 27 2061 26614 50576422
Anaphylactoid shock 56.40 40.27 10 2078 308 50602728
Rash pustular 53.92 40.27 17 2071 6464 50596572
Rash 53.60 40.27 77 2011 437394 50165642
Anaphylactoid reaction 50.61 40.27 14 2074 3392 50599644
Contrast media reaction 50.44 40.27 11 2077 996 50602040

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Contrast media reaction 237.18 39.11 43 2320 762 29571402
Pruritus 180.42 39.11 113 2250 116736 29455428
Urticaria 167.10 39.11 83 2280 54577 29517587
Erythema 136.51 39.11 81 2282 75525 29496639
Contrast media allergy 95.58 39.11 18 2345 394 29571770
Rash 93.98 39.11 94 2269 189725 29382439
Anaphylactic reaction 93.35 39.11 45 2318 27528 29544636
Acute kidney injury 84.10 39.11 104 2259 265163 29307001
Acute generalised exanthematous pustulosis 64.31 39.11 22 2341 5561 29566603
Rash maculo-papular 43.54 39.11 26 2337 24263 29547901
Nephropathy toxic 40.75 39.11 19 2344 10737 29561427
Anaphylactoid reaction 40.35 39.11 12 2351 1933 29570231
Hypotension 39.83 39.11 62 2301 194292 29377872
Swelling face 39.66 39.11 23 2340 20327 29551837

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 324.88 36.41 223 4214 312177 64182118
Urticaria 280.29 36.41 155 4282 147162 64347133
Contrast media reaction 262.17 36.41 52 4385 1760 64492535
Erythema 211.29 36.41 141 4296 186929 64307366
Acute generalised exanthematous pustulosis 152.48 36.41 51 4386 14007 64480288
Rash 134.90 36.41 161 4276 458388 64035907
Acute kidney injury 108.41 36.41 143 4294 449097 64045198
Anaphylactic reaction 102.72 36.41 62 4375 68602 64425693
Rash maculo-papular 87.64 36.41 49 4388 46977 64447318
Contrast media allergy 83.36 36.41 21 4416 2120 64492175
Contrast encephalopathy 80.45 36.41 13 4424 130 64494165
Anaphylactoid reaction 79.57 36.41 24 4413 4714 64489581
Anaphylactoid shock 70.08 36.41 15 4422 739 64493556
Eosinophilia 66.40 36.41 38 4399 38038 64456257
Angioedema 63.24 36.41 44 4393 61777 64432518
Toxic skin eruption 58.80 36.41 28 4409 19256 64475039
Swelling face 57.93 36.41 41 4396 59125 64435170
Nephropathy toxic 55.14 36.41 26 4411 17488 64476807
Rash pustular 51.76 36.41 21 4416 9864 64484431
Dyspnoea 49.87 36.41 134 4303 718540 63775755
Hypotension 47.71 36.41 90 4347 380884 64113411
Flushing 47.59 36.41 41 4396 78607 64415688
Throat irritation 42.41 36.41 27 4410 32684 64461611
Nephropathy 41.12 36.41 17 4420 8369 64485926
Drug ineffective 40.88 36.41 5 4432 840242 63654053
Anaphylactic shock 39.23 36.41 25 4412 30303 64463992
Eyelid oedema 37.94 36.41 18 4419 12261 64482034
Sneezing 37.12 36.41 19 4418 15232 64479063

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08AB09 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA N0000010258 X-Ray Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000180185 Radiographic Contrast Agent
CHEBI has role CHEBI:37338 contrast media

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.43 acidic
pKa2 10.85 acidic
pKa3 11.21 acidic
pKa4 11.63 acidic
pKa5 12.19 acidic
pKa6 13.65 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020982 VUID
N0000148453 NUI
D01474 KEGG_DRUG
4020982 VANDF
C0063757 UMLSCUI
CHEBI:31705 CHEBI
CHEMBL1200507 ChEMBL_ID
DB01249 DRUGBANK_ID
C044834 MESH_SUPPLEMENTAL_RECORD_UI
5692 INN_ID
HW8W27HTXX UNII
3724 PUBCHEM_CID
27729 RXNORM
11441 MMSL
4902 MMSL
d04016 MMSL
006060 NDDF
353962003 SNOMEDCT_US
395750001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2222 INJECTION, SOLUTION 270 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2222 INJECTION, SOLUTION 270 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2222 INJECTION, SOLUTION 270 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2222 INJECTION, SOLUTION 270 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 31 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 31 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 31 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 31 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 31 sections